Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma

Inclusion Criteria: Body mass index (BMI) 18-25, body weight should be ≥ 40kg; Meet the Diagnostic Criteria for AIDS and HIV Infection (WS293-2019), and be diagnosed as HIV seropositive; HIV infection combined with lymphoma, in partial remission or relapsed after initial complete remission, failed induction therapy, but responds to salvage therapy; Age-adjusted IPI 2-3 points; Meet the indications for autologous bone marrow transplantation after clinical evaluation; HIV viral load <1000 copies/ml; Must have the ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: Any HIV-related uncontrolled opportunistic infection, including fungal infection, sepsis, active tuberculosis, weightlessness, severe diarrhea, active opportunistic infections in the central nervous system or active hepatitis B, hepatitis C, and other viral infections such as CMV; Cardiac insufficiency (LVEF<50%), renal insufficiency (creatinine>2mg/dl), hepatic insufficiency (AST/ALT>3 ULN and/or PT <70% unrelated to lymphoma); HAART treatment failure (including at least one NRTI, one NNRTI and two PI) and/or CD4 count < 50/cmm); Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin; Participation of other investigational agents (traditional Chinese medicine is not included) within 3 months； Any concurrent or past medical condition that, in the opinion of the Investigator, would exclude the subject from participation or any psychosocial conditions that would hinder study compliance or follow-up, at the discretion of the Investigator.